Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSR149744C for Conversion of Atrial Fibrillation / Flutter
NCT00232310Phase 2Completed
- Sponsor
- Sanofi
- Start
- Oct 2005
- Primary completion
- Apr 2006
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, double-blind trial of celivarone in Atrial fibrillation (AFib) and atrial flutter (AFL) (3 arms), sponsored by Sanofi. Primary endpoint: Rate of conversion to sinus rhythm at 48 hours. Started Oct 2005; status: completed.
02
Drugs
celivarone
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on NCT00232310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00232310.